Avecho Biotechnology Ltd has released a press release.
FDA meeting provides guidance for TPM/Oxymorphone patch
Filed with ASX ·
6ix hasn’t read this filing yet.
Avecho Biotechnology Limited on 6ix
Story so far
Earlier from Avecho Biotechnology
- Reinstatement to Offical Quotation
- Phosphagenics and Mylan Agree Settlement
- Suspension from Official Quotation
- Phosphagenics Arbitration Award Issued
- Phosphagenics Receives Further Arbitration Process Update
Later from Avecho Biotechnology
- Ashland purchases manufacturing rights for Vital ET and TPM
- Terumo return rights to TPM/Propofol Injectable
- Injectable Portfolio Update - Products Differentiated by TPM
- Appendix 4C - Quarterly
- Appendix 4E and Annual Report 31 December 2019
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology